Loading...

Renascience Inc.

4889.T•JPX
Healthcare
Biotechnology
¥2695.00
¥-238.00(-8.11%)

Renascience Inc. (4889.T) Stock Overview

Explore Renascience Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.2/100

Key Financials

Market Cap34.3B
P/E Ratio302.29
EPS (TTM)$8.88
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Week$1982.78
1 Month$1698.70
3 Months$2103.18
1 Year Target$571.92

4889.T Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Renascience Inc. (4889.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.01, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $571.92.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 302.29 and a market capitalization of 34.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

67.01RSI (14)
204.89MACD
41.69ADX
Stats data is not available for 4889.TStats details for 4889.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 4889.TAnalyst Recommendations details for 4889.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.

CEO

Keisuke Furuta

Employees

4

Headquarters

401 Kyodo Building, Tokyo

Founded

2021

Frequently Asked Questions

;